A Phase 3 interventional study of Alogliptin and Metformin in Diabetes Mellitus, Type 2, sponsored by Takeda. Completed at 201 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-03-26.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 5 that started in 2009, is one of 16 in phase 3, and was the 16th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 23 · Phase 4 9
First in 2005; this study’s year is marked. 5 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 784 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 329 across the 39 interventional studies. Of the 35 that completed or were terminated, 30 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 39 have an industry lead sponsor. The 9 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
105 studies in Diabetes Mellitus, Type 2 by Takeda: none open now, none under way, none of them phase 3. Of 103 finished, 69 (67%) have results posted.
Among the 105 studies in Diabetes Mellitus, Type 2 by Takeda, this one is the 10th largest by enrollment of the 85 interventional ones that give a count, is one of 11 that started in 2009, is one of 45 in phase 3, and was the 51st registered.
Takeda’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 105 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
There are approximately 19 million people in the United States who have been diagnosed with diabetes mellitus, of which 90% to 95% are type 2. The prevalence of type 2 diabetes varies among racial and ethnic populations and has been shown to correlate with age, obesity, family history, history of gestational diabetes and physical inactivity. Over the next decade, a marked increase in the number of adults with diabetes mellitus is expected.
Metformin is the usual choice of first-line therapy for type 2 diabetes. Metformin targets insulin resistance in type 2 diabetes by inhibiting hepatic glucose production and stimulating glucose uptake in skeletal muscle and adipose tissue, which results in a long-term glucose-lowering effect.
Alogliptin is an inhibitor of the dipeptidyl peptidase IV enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo degradation of 2 peptide hormones released in response to nutrient ingestion, namely glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert important effects on islet beta cells to stimulate glucose-dependent insulin secretion as well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion, and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes mellitus. It is expected that inhibition of dipeptidyl peptidase IV will improve glycemic (glucose) control in patients with type 2 diabetes.
Based on the potential, complimentary mechanisms of action of alogliptin and metformin, this study will compare the safety and efficacy of alogliptin and metformin (SYR-322MET) on improving glycemic control in patients with type 2 diabetes mellitus who are inadequately controlled by diet adjustment and exercise alone.
Participants taking part in this study will receive dietary and exercise coaching, and will monitor their own blood glucose concentrations with a home glucose monitor. Participants will also be required to maintain a hypoglycemic diary throughout the course of the study. Participation in this study is expected to last up to 34 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
Drug: Alogliptin Placebo · Drug: Metformin Placebo
Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
Drug: Alogliptin · Drug: Metformin Placebo
Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
Drug: Alogliptin · Drug: Metformin Placebo
Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
Drug: Metformin · Drug: Alogliptin Placebo
Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
Drug: Metformin · Drug: Alogliptin Placebo
Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
Drug: Alogliptin · Drug: Metformin
Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.
Drug: Alogliptin · Drug: Metformin
Alogliptin tablets.
Also known as: SYR-322
Metformin capsules
Also known as: Glucophage, Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Dianben, Diabex, Diaformin
Alogliptin placebo-matching tablets.
Metformin placebo-matching capsules.
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
Time frame: Baseline and Week 26.
Change From Baseline in HbA1c Over Time
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.
Time frame: Baseline and Weeks 4, 8, 12, 16, and 20.
Change From Baseline in Fasting Plasma Glucose Over Time
The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.
Time frame: Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.
Participants took part in the study at 198 investigative sites worldwide from 16 November 2009 to 30 June 2011.
| Milestone | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID |
|---|---|---|---|---|---|---|---|
| Started | 109 | 112 | 113 | 114 | 111 | 111 | 114 |
| Received study treatment | 106 | 112 | 110 | 109 | 111 | 106 | 114 |
| Completed | 74 | 89 | 71 | 94 | 95 | 92 | 94 |
| Not completed | 35 | 23 | 42 | 20 | 16 | 19 | 20 |
| Withdrew: Adverse event | 4 | 4 | 7 | 3 | 2 | 5 | 11 |
| Withdrew: Major protocol deviation | 2 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 8 | 7 | 2 | 5 | 2 | 2 |
| Withdrew: Withdrawal by subject | 13 | 8 | 16 | 10 | 6 | 8 | 5 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 9 | 3 | 6 | 2 | 1 | 2 | 1 |
| Withdrew: Physician decision | 2 | 0 | 2 | 1 | 1 | 1 | 1 |
| Withdrew: Other | 1 | 0 | 1 | 0 | 1 | 0 | 0 |
The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).
| percentage glycosylated hemoglobin | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID |
|---|---|---|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 | 0.15 ± 0.094 | -0.52 ± 0.094 | -0.56 ± 0.093 | -0.65 ± 0.094 | -1.11 ± 0.092 | -1.22 ± 0.094 | -1.55 ± 0.090 |
The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) was assessed at Weeks 4, 8, 12, 16 and 20. Least squares means are from an analysis of covariance (ANCOVA) model with treatment and geographic region as fixed effects, and baseline HbA1c as a covariate.
| percentage glycosylated hemoglobin | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID |
|---|---|---|---|---|---|---|---|
| Week 4 (n=95, 97, 89, 94, 102, 94, 101) | 0.09 ± 0.058 | -0.34 ± 0.057 | -0.42 ± 0.060 | -0.37 ± 0.058 | -0.58 ± 0.056 | -0.70 ± 0.058 | -0.75 ± 0.056 |
| Week 8 (n=102, 104, 104, 103, 108, 102, 111) | 0.08 ± 0.073 | -0.51 ± 0.073 | -0.58 ± 0.072 | -0.59 ± 0.073 | -0.86 ± 0.071 | -1.08 ± 0.073 | -1.17 ± 0.070 |
| Week 12 (n=102, 104, 104, 103, 108, 102, 111) | 0.12 ± 0.081 | -0.53 ± 0.080 | -0.62 ± 0.080 | -0.68 ± 0.081 | -1.02 ± 0.079 | -1.22 ± 0.081 | -1.40 ± 0.078 |
| Week 16 (n=102, 104, 104, 103, 108, 102, 111) | 0.13 ± 0.087 | -0.58 ± 0.087 | -0.63 ± 0.086 | -0.72 ± 0.087 | -1.09 ± 0.085 | -1.26 ± 0.087 | -1.50 ± 0.084 |
| Week 20 (n=102, 104, 104, 103, 108, 102, 111) | 0.12 ± 0.092 | -0.57 ± 0.091 | -0.59 ± 0.091 | -0.68 ± 0.092 | -1.14 ± 0.089 | -1.25 ± 0.092 | -1.54 ± 0.088 |
The change from Baseline in fasting plasma glucose was assessed at Weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as fixed effects, and baseline fasting plasma glucose as a covariate.
| mg/dL | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID |
|---|---|---|---|---|---|---|---|
| Week 1 (n=102, 103, 94, 95, 104, 101, 109) | 5.7 ± 3.40 | -3.9 ± 3.38 | -11.9 ± 3.54 | -12.6 ± 3.52 | -23.1 ± 3.36 | -32.7 ± 3.41 | -36.3 ± 3.29 |
| Week 2 (n=105, 112, 105, 102, 108, 106, 111) | 4.6 ± 3.58 | -7.4 ± 3.46 | -11.6 ± 3.58 | -14.5 ± 3.63 | -22.2 ± 3.53 | -34.5 ± 3.56 | -43.6 ± 3.48 |
| Week 4 (n=105, 112, 106, 106, 110, 106, 111) | 7.2 ± 3.69 | -11.5 ± 3.57 | -16.6 ± 3.67 | -16.9 ± 3.67 | -29.0 ± 3.60 | -37.6 ± 3.67 | -44.1 ± 3.58 |
| Week 8 (n=105, 112, 106, 106, 110, 106, 112) | 7.1 ± 4.00 | -10.9 ± 3.87 | -12.1 ± 3.98 | -11.8 ± 3.98 | -30.7 ± 3.91 | -32.9 ± 3.98 | -43.8 ± 3.87 |
| Week 12 (n=105, 112, 106, 106, 110, 106, 112) | 11.6 ± 4.16 | -9.7 ± 4.03 | -14.7 ± 4.14 | -14.0 ± 4.14 | -30.7 ± 4.06 | -31.6 ± 4.14 | -44.7 ± 4.03 |
| Week 16 (n=105, 112, 106, 106, 110, 106, 112) | 10.1 ± 4.17 | -7.1 ± 4.04 | -14.7 ± 4.15 | -13.3 ± 4.15 | -33.5 ± 4.07 | -35.9 ± 4.15 | -47.7 ± 4.04 |
| Week 20 (n=105, 112, 106, 106, 110, 106, 112) | 8.7 ± 4.36 | -9.2 ± 4.22 | -12.3 ± 4.34 | -10.9 ± 4.34 | -35.1 ± 4.25 | -33.8 ± 4.34 | -44.6 ± 4.22 |
| Week 26 (n=105, 112, 106, 106, 110, 106, 112) | 12.4 ± 4.52 | -6.1 ± 4.37 | -9.7 ± 4.49 | -11.5 ± 4.49 | -31.9 ± 4.41 | -31.7 ± 4.49 | -45.9 ± 4.37 |
Collected over Adverse events that occurred after the first dose of double-blind study medication and within 14 days after the last dose of double-blind study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 3/106 (2.8%) | 50/106 (47.2%) |
| Alogliptin 25 QD | — | 1/112 (0.9%) | 38/112 (33.9%) |
| Alogliptin 12.5 BID | — | 4/110 (3.6%) | 34/110 (30.9%) |
| Metformin 500 BID | — | 3/109 (2.8%) | 44/109 (40.4%) |
| Metformin 1000 BID | — | 2/111 (1.8%) | 43/111 (38.7%) |
| Alogliptin 12.5 BID + Metformin 500 BID | — | 2/106 (1.9%) | 40/106 (37.7%) |
| Alogliptin 12.5 BID + Metformin 1000 BID | — | 2/114 (1.8%) | 37/114 (32.5%) |
| Event | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID |
|---|---|---|---|---|---|---|---|
| Myocardial ischaemiaCardiac disorders | 1/106 | 0/112 | 0/110 | 0/109 | 0/111 | 0/106 | 0/114 |
| TremorNervous system disorders | 1/106 | 0/112 | 0/110 | 0/109 | 0/111 | 0/106 | 0/114 |
| Non-cardiac chest painGeneral disorders | 0/106 | 0/112 | 0/110 | 0/109 | 0/111 | 1/106 | 0/114 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/106 | 0/112 | 0/110 | 0/109 | 0/111 | 0/106 | 0/114 |
| DelusionPsychiatric disorders | 0/106 | 0/112 | 0/110 | 0/109 | 0/111 | 1/106 | 0/114 |
| Angina pectorisCardiac disorders | 0/106 | 0/112 | 0/110 | 1/109 | 0/111 | 0/106 | 0/114 |
| Ankle fractureInjury, poisoning and procedural complications | 0/106 | 0/112 | 0/110 | 1/109 | 0/111 | 0/106 | 0/114 |
| Alveolitis allergicRespiratory, thoracic and mediastinal disorders | 0/106 | 0/112 | 0/110 | 1/109 | 0/111 | 0/106 | 0/114 |
| Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 0/106 | 0/112 | 0/110 | 1/109 | 0/111 | 0/106 | 0/114 |
| PneumoniaInfections and infestations | 0/106 | 0/112 | 1/110 | 0/109 | 0/111 | 0/106 | 0/114 |
| Event | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID |
|---|---|---|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 28/106 | 19/112 | 13/110 | 19/109 | 9/111 | 8/106 | 1/114 |
| DiarrhoeaGastrointestinal disorders | 3/106 | 1/112 | 3/110 | 4/109 | 10/111 | 6/106 | 8/114 |
| Creatinine renal clearance decreasedInvestigations | 4/106 | 1/112 | 4/110 | 0/109 | 6/111 | 5/106 | 9/114 |
| Upper respiratory tract infectionInfections and infestations | 3/106 | 3/112 | 3/110 | 4/109 | 3/111 | 8/106 | 2/114 |
| HeadacheNervous system disorders | 3/106 | 6/112 | 5/110 | 8/109 | 4/111 | 7/106 | 6/114 |
| HypertensionVascular disorders | 5/106 | 3/112 | 2/110 | 6/109 | 1/111 | 5/106 | 8/114 |
| DyspepsiaGastrointestinal disorders | 3/106 | 0/112 | 1/110 | 0/109 | 2/111 | 0/106 | 8/114 |
| DyslipidaemiaMetabolism and nutrition disorders | 6/106 | 1/112 | 2/110 | 7/109 | 6/111 | 6/106 | 2/114 |
| NasopharyngitisInfections and infestations | 2/106 | 7/112 | 1/110 | 2/109 | 4/111 | 3/106 | 2/114 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 3/106 | 3/112 | 1/110 | 3/109 | 6/111 | 6/106 | 1/114 |
| Age Continuous(years) | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 53.1 ± 9.60 | 52.6 ± 9.38 | 53.7 ± 9.70 | 54.6 ± 10.20 | 52.6 ± 11.30 | 53.7 ± 11.59 | 54.6 ± 10.42 | 53.5 ± 10.33 |
| Age, Customized(participants) | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID | Total |
|---|---|---|---|---|---|---|---|---|
| <65 years | 100 | 103 | 96 | 95 | 94 | 91 | 96 | 675 |
| ≥65 years | 9 | 9 | 17 | 19 | 17 | 20 | 18 | 109 |
| Sex: Female, Male(Participants) | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 54 | 64 | 50 | 67 | 60 | 63 | 52 | 410 |
| Male | 55 | 48 | 63 | 47 | 51 | 48 | 62 | 374 |
| Race/Ethnicity, Customized(participants) | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 45 | 43 | 43 | 45 | 42 | 45 | 39 | 302 |
| Not Hispanic or Latino | 64 | 69 | 70 | 69 | 69 | 66 | 75 | 482 |
| Race/Ethnicity, Customized(participants) | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 8 | 5 | 3 | 6 | 9 | 5 | 41 |
| Asian | 20 | 17 | 21 | 19 | 20 | 20 | 26 | 143 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 8 | 3 | 3 | 6 | 6 | 6 | 5 | 37 |
| White | 76 | 84 | 83 | 85 | 79 | 76 | 78 | 561 |
| Multiracial | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 31.15 ± 5.269 | 30.81 ± 5.219 | 30.36 ± 5.159 | 30.19 ± 4.842 | 30.51 ± 5.043 | 30.92 ± 5.353 | 31.04 ± 5.375 | 30.71 ± 5.173 |
| Diabetes Duration(years) | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 4.25 ± 4.778 | 3.65 ± 4.119 | 3.97 ± 4.800 | 3.78 ± 3.904 | 4.08 ± 4.587 | 4.13 ± 4.777 | 4.22 ± 4.972 | 4.01 ± 4.563 |
| Baseline HbA1c(participants) | Placebo | Alogliptin 25 QD | Alogliptin 12.5 BID | Metformin 500 BID | Metformin 1000 BID | Alogliptin 12.5 BID + Metformin 500 BID | Alogliptin 12.5 BID + Metformin 1000 BID | Total |
|---|---|---|---|---|---|---|---|---|
| ≤8.5% | 65 | 67 | 67 | 67 | 66 | 66 | 67 | 465 |
| >8.5% | 44 | 45 | 46 | 47 | 45 | 45 | 47 | 319 |
Showing the first 100 of 201 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2009, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alogliptin · Metformin